Kyungbo Pharma unit of Chongkundang gets court stay on approval cancellation pending appeal
A court injunction suspends Kyungbo Pharmaceutical’s approval-cancellation effect until 30 days after the appellate ruling; affected sales exposure remains KRW 13.48 billion (5.65% of 2024 revenue), with suspension starting June 24, 2025.